Request Demo
Last update 15 Jul 2026
HR-004
Last update 15 Jul 2026
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms Anti-CD19 anti-CD22 bispecific CAR-T cell therapy (Hrain Biotechnology), Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy(Hrain Biotechnology), Anti-human CD19-CD22 T cell therapy(Hrain Biotechnology Co. Ltd.) + [3] |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD22 modulators(CD22 modulators), Immunologic cytotoxicity |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with HR-004NCT05651178
A Early Phase 1 Clinical Trial To Evaluate the Safety and Efficacy of Human CD19-CD22 Targeted T Cells Injection for Subjects With Central Nervous System Involvement of Refractory/Relapsed B Cell Malignancies
NCT05223686
A Phase I Clinical Study To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for In Subjects With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
NCT04303520
A Phase I Clinical Trial of T-Cells Targeting CD19 and CD22 for Subjects With CD19-positive Acute Lymphoblastic Leukemia
100 Clinical Results associated with HR-004
Login to view more data
100 Translational Medicine associated with HR-004
Login to view more data
100 Patents (Medical) associated with HR-004
Login to view more data
100 Deals associated with HR-004
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Central nervous system leukaemia | Phase 1 | China | 12 Aug 2022 | |
| Lupus Vasculitis, Central Nervous System | Phase 1 | China | 12 Aug 2022 | |
| Refractory Central Nervous System Lymphoma | Phase 1 | China | 12 Aug 2022 | |
| Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | China | 21 Jan 2022 | |
| Refractory B Acute Lymphoblastic Leukemia | Phase 1 | China | 21 Jan 2022 | |
| CD19 positive Acute Lymphoblastic Leukemia | Phase 1 | China | 03 May 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free